Clinical Trial Detail

NCT ID NCT02812693
Title Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Joanne Jeter
Indications

melanoma

Therapies

Imatinib + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST